Pharmbio Korea Co., Ltd. agreed to acquire certain assets of INSYS Therapeutics, Inc. (OTCPK:INSY.Q) on September 25, 2019. Consideration for the transferred assets an amount in cash equal to $1.2 million. Buyer has, pursuant to the terms of the Escrow Agreement, deposited with Citibank, N.A., in its capacity as escrow agent the sum of $0.2 million by wire transfer of immediately available funds to be released by the escrow agent and delivered to either Pharmbio Korea Co., Ltd. or INSYS Therapeutics, Inc. in accordance with the provisions of this agreement and the Escrow Agreement. Board of Directors of INSYS Therapeutics, Inc. and Pharmbio Korea Co., Ltd. approved the execution, delivery, and performance of this Agreement. Pursuant to the Escrow Agreement, the Escrowed Funds together with all accrued investment income thereon shall be distributed If the Closing shall occur, the Escrowed Funds shall be released to INSYS Therapeutics, Inc. by the Escrow Agent at the Closing and applied towards the purchase price payable by Pharmbio Korea Co., Ltd. to INSYS Therapeutics, Inc. and all accrued investment income thereon shall be delivered to Pharmbio Korea Co., Ltd. at the closing. If this Agreement is terminated by INSYS Therapeutics, Inc., the Escrowed Funds, together with all accrued investment income thereon, shall be delivered to INSYS Therapeutics, Inc. If this Agreement is terminated for any reason other than by Seller pursuant to Section 12.1, the Escrowed Funds, together with all accrued investment income thereon, shall in each case be returned to Buyer. The closing of the purchase and sale of the transferred assets shall take place at the offices of Weil, Gotshal & Manges LLP, 767 Fifth Avenue, New York, NY 10153 on the third business day following the date on which all of the conditions to each party’s obligations under ARTICLE XI have been satisfied or (if permitted) waived, or at such other time, date and/or place as is mutually agreed to by the parties hereto.